Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations

Timothy Charles Greiner, A. A. Abou-Elella, B. N. Smir, A. Orazi, Steven Heye Hinrichs, J. Anderson, T. Gross, Philip Jay Bierman, R. Hauke

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Posttransplant lymphoproliferative disorders (PTLDs), which are highly associated with Epstein-Barr virus infection, have a low frequency of molecular genetic abnormalities. Recently it has been suggested certain EBV substrains may be associated with specific lymphoma subtypes. The goals of our study were two fold: 1) to determine the prevalence of EBNA-1 substrains and prognostic utility in PTLD and 2) to determine the incidence of p53 gene mutations and p53 protein overexpression in 32 EBV-positive PTLD cases. Tumor DNA was sequenced to identify EBNA-1 substrains at codon 487 and p53 gene mutations in exons 5-8. The PTLD samples contained the following EBNA-1 substrains: P-thr in 17/32 (53%), P-ala in 11/32 (34%), and V-leu in 4/32 (13%). More heterogeneity within major subtypes was seen in the PTLD cases than in the referral group. A second group of 25 referral (non-PTLD) samples including infectious mononucleosis (6) and sequential EBV positive virology samples (19) contained P-thr in 17/25 (68%); P-ala in 2/25 (8%); and V-leu in 6/25 (24%). In the 29 B-cell PTLD the time to presentation was an average of 13.3 months in the P-ala group, 16.6 months in the P-thr group, and 40.6 months in the V-leu group: (p > 0.05). There was no difference in survival in patients (median overall - 60 months) between the three different substrains of EBNA-1 (Log rank test, p = 0.39). One of 31 (4.1%) cases (a diffuse large cell B-cell) had a p53 mutation. Seven of 31 (23%) cases (all B-cell), including the p53 mutated case, had over-expression of p53 protein. We conclude EBNA-1 substrains vary in PTLD and suggest the pattern reflects the geographical incidence of substrains in the region. We also conclude p53 mutations are not a significant molecular genetic abnormality in PTLD.

Original languageEnglish (US)
Pages (from-to)563-576
Number of pages14
JournalLeukemia and Lymphoma
Volume38
Issue number5-6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Molecular Epidemiology
Lymphoproliferative Disorders
Human Herpesvirus 4
Mutation
B-Lymphocytes
p53 Genes
Molecular Biology
Referral and Consultation
EBV-encoded nuclear antigen 1
Infectious Mononucleosis
Virology
Epstein-Barr Virus Infections
Incidence
Codon
Exons
Lymphoma
Proteins
Survival
DNA

Keywords

  • EBNA-1
  • Lymphoproliferative disorders
  • Molecular epidemiology
  • PTLD
  • Transplantation
  • p21
  • p5

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations. / Greiner, Timothy Charles; Abou-Elella, A. A.; Smir, B. N.; Orazi, A.; Hinrichs, Steven Heye; Anderson, J.; Gross, T.; Bierman, Philip Jay; Hauke, R.

In: Leukemia and Lymphoma, Vol. 38, No. 5-6, 01.01.2000, p. 563-576.

Research output: Contribution to journalArticle

@article{bc062acc807d40a7b35ec6e4ebdbe941,
title = "Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations",
abstract = "Posttransplant lymphoproliferative disorders (PTLDs), which are highly associated with Epstein-Barr virus infection, have a low frequency of molecular genetic abnormalities. Recently it has been suggested certain EBV substrains may be associated with specific lymphoma subtypes. The goals of our study were two fold: 1) to determine the prevalence of EBNA-1 substrains and prognostic utility in PTLD and 2) to determine the incidence of p53 gene mutations and p53 protein overexpression in 32 EBV-positive PTLD cases. Tumor DNA was sequenced to identify EBNA-1 substrains at codon 487 and p53 gene mutations in exons 5-8. The PTLD samples contained the following EBNA-1 substrains: P-thr in 17/32 (53{\%}), P-ala in 11/32 (34{\%}), and V-leu in 4/32 (13{\%}). More heterogeneity within major subtypes was seen in the PTLD cases than in the referral group. A second group of 25 referral (non-PTLD) samples including infectious mononucleosis (6) and sequential EBV positive virology samples (19) contained P-thr in 17/25 (68{\%}); P-ala in 2/25 (8{\%}); and V-leu in 6/25 (24{\%}). In the 29 B-cell PTLD the time to presentation was an average of 13.3 months in the P-ala group, 16.6 months in the P-thr group, and 40.6 months in the V-leu group: (p > 0.05). There was no difference in survival in patients (median overall - 60 months) between the three different substrains of EBNA-1 (Log rank test, p = 0.39). One of 31 (4.1{\%}) cases (a diffuse large cell B-cell) had a p53 mutation. Seven of 31 (23{\%}) cases (all B-cell), including the p53 mutated case, had over-expression of p53 protein. We conclude EBNA-1 substrains vary in PTLD and suggest the pattern reflects the geographical incidence of substrains in the region. We also conclude p53 mutations are not a significant molecular genetic abnormality in PTLD.",
keywords = "EBNA-1, Lymphoproliferative disorders, Molecular epidemiology, PTLD, Transplantation, p21, p5",
author = "Greiner, {Timothy Charles} and Abou-Elella, {A. A.} and Smir, {B. N.} and A. Orazi and Hinrichs, {Steven Heye} and J. Anderson and T. Gross and Bierman, {Philip Jay} and R. Hauke",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/10428190009059276",
language = "English (US)",
volume = "38",
pages = "563--576",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations

AU - Greiner, Timothy Charles

AU - Abou-Elella, A. A.

AU - Smir, B. N.

AU - Orazi, A.

AU - Hinrichs, Steven Heye

AU - Anderson, J.

AU - Gross, T.

AU - Bierman, Philip Jay

AU - Hauke, R.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Posttransplant lymphoproliferative disorders (PTLDs), which are highly associated with Epstein-Barr virus infection, have a low frequency of molecular genetic abnormalities. Recently it has been suggested certain EBV substrains may be associated with specific lymphoma subtypes. The goals of our study were two fold: 1) to determine the prevalence of EBNA-1 substrains and prognostic utility in PTLD and 2) to determine the incidence of p53 gene mutations and p53 protein overexpression in 32 EBV-positive PTLD cases. Tumor DNA was sequenced to identify EBNA-1 substrains at codon 487 and p53 gene mutations in exons 5-8. The PTLD samples contained the following EBNA-1 substrains: P-thr in 17/32 (53%), P-ala in 11/32 (34%), and V-leu in 4/32 (13%). More heterogeneity within major subtypes was seen in the PTLD cases than in the referral group. A second group of 25 referral (non-PTLD) samples including infectious mononucleosis (6) and sequential EBV positive virology samples (19) contained P-thr in 17/25 (68%); P-ala in 2/25 (8%); and V-leu in 6/25 (24%). In the 29 B-cell PTLD the time to presentation was an average of 13.3 months in the P-ala group, 16.6 months in the P-thr group, and 40.6 months in the V-leu group: (p > 0.05). There was no difference in survival in patients (median overall - 60 months) between the three different substrains of EBNA-1 (Log rank test, p = 0.39). One of 31 (4.1%) cases (a diffuse large cell B-cell) had a p53 mutation. Seven of 31 (23%) cases (all B-cell), including the p53 mutated case, had over-expression of p53 protein. We conclude EBNA-1 substrains vary in PTLD and suggest the pattern reflects the geographical incidence of substrains in the region. We also conclude p53 mutations are not a significant molecular genetic abnormality in PTLD.

AB - Posttransplant lymphoproliferative disorders (PTLDs), which are highly associated with Epstein-Barr virus infection, have a low frequency of molecular genetic abnormalities. Recently it has been suggested certain EBV substrains may be associated with specific lymphoma subtypes. The goals of our study were two fold: 1) to determine the prevalence of EBNA-1 substrains and prognostic utility in PTLD and 2) to determine the incidence of p53 gene mutations and p53 protein overexpression in 32 EBV-positive PTLD cases. Tumor DNA was sequenced to identify EBNA-1 substrains at codon 487 and p53 gene mutations in exons 5-8. The PTLD samples contained the following EBNA-1 substrains: P-thr in 17/32 (53%), P-ala in 11/32 (34%), and V-leu in 4/32 (13%). More heterogeneity within major subtypes was seen in the PTLD cases than in the referral group. A second group of 25 referral (non-PTLD) samples including infectious mononucleosis (6) and sequential EBV positive virology samples (19) contained P-thr in 17/25 (68%); P-ala in 2/25 (8%); and V-leu in 6/25 (24%). In the 29 B-cell PTLD the time to presentation was an average of 13.3 months in the P-ala group, 16.6 months in the P-thr group, and 40.6 months in the V-leu group: (p > 0.05). There was no difference in survival in patients (median overall - 60 months) between the three different substrains of EBNA-1 (Log rank test, p = 0.39). One of 31 (4.1%) cases (a diffuse large cell B-cell) had a p53 mutation. Seven of 31 (23%) cases (all B-cell), including the p53 mutated case, had over-expression of p53 protein. We conclude EBNA-1 substrains vary in PTLD and suggest the pattern reflects the geographical incidence of substrains in the region. We also conclude p53 mutations are not a significant molecular genetic abnormality in PTLD.

KW - EBNA-1

KW - Lymphoproliferative disorders

KW - Molecular epidemiology

KW - PTLD

KW - Transplantation

KW - p21

KW - p5

UR - http://www.scopus.com/inward/record.url?scp=0033862927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033862927&partnerID=8YFLogxK

U2 - 10.3109/10428190009059276

DO - 10.3109/10428190009059276

M3 - Article

C2 - 10953978

AN - SCOPUS:0033862927

VL - 38

SP - 563

EP - 576

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -